Depomed CEO Jim Schoeneck and his team may have thought they were in the clear. It's been about nine months since the maker of drugs for severe pain snubbed an approach from Horizon Pharma.
↧
Depomed CEO Jim Schoeneck and his team may have thought they were in the clear. It's been about nine months since the maker of drugs for severe pain snubbed an approach from Horizon Pharma.